Constitutional laminopathies such as the Dunnigan familial partial lipodystrophy, are severe diseases caused by mutations in A-type lamins and share several features with metabolic syndrome (MS). In this study, we hypothesized that MS may be, in some cases, a mild form of laminopathies and use the abnormal cell nucleus phenotype observed in these diseases as a primary screening test in patients suffering from common MS.
Introduction
The metabolic syndrome (MS) is a cluster of metabolic abnormalities affecting 30% of North Americans and 23% of Europeans (1, 2) . These abnormalities include abdominal adiposity, impaired fasting glucose and hyper-insulinemia both reflecting insulin resistance, dyslipidemia, hepatic steatosis, and high blood pressure (1) . Interestingly, MS-associated features such as insulin resistance and dyslipidemia are also frequently observed in monogenic disorders such as the Dunnigan familial partial lipodystrophy (FPLD) (3, 4) suggesting that such inherited disorders could provide important insights for understanding typical MS.
FPLD belongs to laminopathies, a large group of human diseases due to mutations in genes encoding the nuclear lamins and associated proteins (5) . A-type lamins form a nucleoplasmic network of structural proteins, the nuclear matrix; they are also localised at the inner surface of the nuclear envelope where they form the nuclear lamina together with other proteins such as B-type lamins or nucleoplasmic domain of some nuclear envelop proteins.
Lamins have multiple functions, including the maintenance of the nuclear structure and shape, heterochromatin organisation and regulation of gene transcription (6) .
A-type lamins, lamin A and C, are both encoded by LMNA but differ from each other because of an alternative splice site in LMNA exon 10. Lamin C is produced directly in its mature form whereas lamin A is first produced as a precursor, the prelamin A, which then undergoes a series of 4 posttranslational modifications (4) . To generate mature lamin A protein, prelamin A is first farnesylated by the farnesyl-transferase, a heterodimer enzyme encoded by the FNTA and FNTB genes, then cleaved either by the zinc metalloprotease ZMPSTE24 or by RCE1. The following steps include a carboxy-methylation by the isoprenylcysteine carboxyl methyltransferase (encoded by ICMT) and a second cleavage by the zinc metalloprotease ZMPSTE24. In humans, genetic variants in ZMPSTE24 are known to cause 2 at INSERM on hmg.oxfordjournals.org Downloaded from different laminopathies (ie, Mandibuloacral dysplasia, MAD, and Restrictive Dermopathy (7, 8) ), while ZMPSTE24-null mice exhibit decreased blood glucose and insulin concentrations as well as an altered lipid metabolism (9) . There has been considerable interest in the association between common LMNA single nucleotide polymorphisms (SNPs) and components of the MS with conflicting results reported, some of them suggesting modest positive associations whereas others, based on studies with larger sample size, did not demonstrate any convincing evidence for an effect of LMNA SNPs on risk for type 2 diabetes mellitus or MS (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) .
However, it is not known whether rare DNA sequence variants of LMNA or of the 4 other genes encoding enzymes involved in lamin A maturation collectively contribute to common MS.
In this study, we hypothesized that MS may represent in some cases, a mild form of laminopathy and used the cell nucleus phenotype observed in several of these diseases (22) as a screening test in patients suffering from common MS. For this purpose, 100 consecutive patients with MS were systematically enrolled for clinical data collection, and 87 were investigated for nuclear shape abnormalities and lamin A nucleoplasmic distribution.
Concomitantly, LMNA and 4 other genes encoding proteins involved in the lamin A maturation pathway were investigated by direct sequencing. 
Results

Cell studies
Among the 100 patients enrolled in the study, 87 were available for cell investigations.
Out of these 87 patients, 10 (11.5%) harboured the two selection criteria for abnormal nuclear phenotype (Table 1) . Only one patient harboured just one criterion (24% of dysmorphic nuclei) but as there was no lamin A/C staining abnormalities, he was classified as having a normal phenotype. Interestingly, two of the 10 patients with abnormal phenotype were siblings. In order to confirm these abnormalities on another cell type, we analyzed the cellular phenotype in cultured dermal fibroblasts which were available for 7 of the 10 patients with abnormalities. We confirmed the abnormal phenotype identified in lymphoblastoid cells for all 7 with a high rate of dysmorphic nuclei (mean 30%) and an abnormal lamin A/C staining (reduced signal, heterogeneous staining with aggregates). Blebbing nuclei were frequent and associated with the reduction or the absence of lamin B1 staining in blebs (Figure 1 ). For 5 of the 10 patients, the nuclear pattern of NuMA (Nuclear Mitotic Apparatus) protein was abnormal with a heterogeneous staining that could reflect a profound nuclear matrix defect No missense or splice sites variation or copy-number variations (CNV) in the 5 genes was identified in the 7 remaining patients with nuclear defects.
In the group of the 77 patients without nuclear defects and in the group of 13 patients not tested for these nuclear abnormalities, no missense or splice sites variation was identified either in LMNA or in ZMPSTE24; Regarding the 3 other tested genes, 2 missense mutations in heterozygous condition were detected in FNTA: p.P27L and p.T375A. However, as these variations were not associated with nuclear defects, they have not been considered as lamin altering mutations for the time being.
Expression studies on lymphoblastoid cells were conducted in 2 subgroups of 7 patients with and 8 without the nuclear defects, both groups being matched for age and sex. No significant differences were noted between the 2 groups either in the levels of lamin A/C transcripts expression or in the protein levels ( Figure S2 ). 
Discussion
The past decade has seen the emergence of links between the nuclear envelope and several diseases (23) . Undoubtedly, is the identification of more than 10 different diseases resulting from mutations within LMNA along with a further seven diseases or anomalies due to defects in other lamin-associated nuclear envelope proteins that has revitalized interest in these proteins. Our study is the first to systematically assess typical features of laminopathies such as nuclear shape abnormalities in a cohort of individuals with MS. Following this approach, 10 patients (about 11%) displayed abnormalities of the nuclear shape and lamin A/C nuclear distribution. Moreover, these patients also presented a reduction or the absence of lamin B1 staining in blebs which is another typical feature seen in laminopathies (9, 24) . To avoid a possible effect due to cell transformation in lymphoblastoid cells (i.e. overestimation of nuclear abnormalities), we analysed skin fibroblasts for 7 out of the 10 patients and confirmed the results in all cases.
Three of the 10 individuals with anomalies of nuclear envelope had functionally significant sequence variations in LMNA or ZMPSTE24. It has been already observed that LMNA mutations may be characterized in individuals referred for lipodystrophy and/or android adiposity, insulin resistance or altered glucose tolerance (25) but to our knowledge, we provide here the first study describing the prevalence of laminopathy in MS. In our cohort of patients with metabolic syndrome, genetic mutations affecting A-type lamins or ZMPSTE24 are far from being uncommon, with a prevalence of 3%. None of these 3 mutations was detected in a group of 120 healthy controls, nor was reported in the 1000 Genomes Project database (http://www.ncbi.nlm.nih.gov/projects). lamin A mutation leads to the reduction of lamin A and C expression but seems to have no effect in the nuclear localization of the protein despite the vicinity of NLS. No functionally significant variations of the five sequenced genes were observed in the 7 remaining individuals with nuclear abnormalities but the fact that two of these 7 individuals are relatives is in favour of a constitutional cause for these abnormalities. In an attempt to go further in the characterization of molecular basis for nuclear abnormalities in this subgroup of 7 patients, we screened also RCE1. This gene was not included initially in the design of the study given that the Ras Converting Enzyme, even if being responsible of the first cleavage of prelamin A, is not lamin A specific but is also involved in proteolytic processing of other farnesylated proteins, including Ras. Again, no variation of any kind was detected after direct sequencing.
Because our selection criteria included nuclear lamin A distribution, we suggest that these 7 patients presented a nuclear envelope or nucleoplasm-related disorders, involving a partner of lamins not investigated in this study such as Emerin (26) or Nesprin-1 and -2 (27) or a yet unknown partner. In these seven individuals, sequencing of other genes involved in nuclear envelope integrity is underway to find other functional variants that may be responsible for the nuclear abnormalities observed. We evidenced no relationship between the clinical and biological characteristics of the patients and the presence of a laminopathy. Individuals with nuclear abnormalities were younger than those without, excluding an age effect. No differences in BMI, in adipose tissue repartition (particularly no differences in subcutaneous thigh development evaluated by TC/BMI) and in the frequency of diabetes or hypertension were observed. The severity of the metabolic phenotype in our 10 patients with laminopathy was heterogeneous; nevertheless triglycerides and ALT were significantly increased and median age and age at diabetes diagnosis were significantly lower, when compared to patients without laminopathy, indicating a more severe phenotype. It must be underlined that none of the 10 patients presented the characteristic morphotype of the Dunnigan syndrome.
Our results imply that a significant proportion of the common MS should be considered as a laminopathy and not only the severe forms as previously described (25). It thus extends the indications for screening for lamin A-related defect in diabetes or MS even in patients without major lipodystrophy. One of the 10 patients presented a dilated cardiomyopathy and another one ventricular arrythmia underlining the importance of this screening linked to the potential cardiac rhythm abnormalities and sudden death that might be associated with laminopathies (28-30).
In conclusion, laminopathies are frequent in patients with MS. Screening for genetic mutations in the A-type lamins and its partners can be recommended in these patients even without specific clinical signs of laminopathy. 
Cell studies
Immunofluorescence microscopy
Blood samples were used to establish Epstein Barr Virus-immortalized lymphoblastoid cell lines. Fibroblasts were obtained from a skin biopsy. All analyses were performed at passage 2 for fibroblasts. Lymphoblastoid cells or fibroblasts from two nonobese, non-diabetic individuals were used as controls (aged 42 and 36, respectively).
We used an immunofluorescence (IF) protocol described elsewhere (32). Primary antibodies list is available on request. The association of the two following criteria was considered to characterize an abnormal phenotype: 1/ a percentage of dysmorphic nuclei up to 20%, and 2/ an abnormal lamin A/C staining in the dysmorphic nuclei. These two criteria were chosen according to previously published data (25, 33). A mean of 500 nuclei were analysed for prelamin A staining and 200 nuclei for all other staining. IF was performed first on lymphoblastoid cells. Then, abnormal cellular phenotypes were confirmed, when available, on skin fibroblasts. 
Western Blotting
Protein extractions from cultured fibroblasts and nuclear matrix protein separation from EBV-immortalized lymphoblastoid cells were performed as previously described (24, 34 
Prelamin A processing study
Prelamin A processing was studied on fibroblasts at passage 5 using the "Prelamin A were performed.
Statistical analyses
The main clinical and metabolic characteristics of individuals with and without nuclear abnormalities were compared using the Fischer exact test for qualitative variables and the Mann-Whitney test for quantitative variables. It is unlikely that these methods, known to be valid for unrelated observations, could be influenced by the presence of one pair of relatives. 
